Specificity of 17β-oestradiol and benzo[α]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432

1. Eight human cytochrome P4501B1 (CYP1B1) allelic variants, namely Arg48Ala119Leu432, Arg48Ala119Val432, Gly48Ala119Leu432, Gly48Ala119Val432, Arg48Ser119Leu432, Arg48Ser119Val432, Gly48Ser119Leu432 and Gly48Ser119Val432 (all with Asn453), were expressed in Escherichia coli together with human NADPH-P450 reductase and their catalytic specificities towards oxidation of 17β-oestradiol and benzo[α]pyrene were determined. 2. All of the CYP1B1 variants expressed in bacterial membranes showed Fe2+·CO versus Fe2+ difference spectra with wavelength maxima at 446nm and they reacted with antibodies raised against recombinant human CYP1B1 in immunoblots. The ratio of expression of the reductase to CYP1B1 in these eight preparations ranged from 0.2 to 0.5. 3. CYP1B1 Arg48 variants tended to have higher activities for 17β-oestradiol 4-hydroxylation than Gly48 variants, although there were no significant variations in 17β-oestradiol 2-hydroxylation activity in these eight CYP1B1 variants. Interestingly, ratios of formation of 17β-oestradiol 4-hydroxylation to 2-hydroxylation by these CYP1B1 variants were higher in all of the Val432 forms than the corresponding Leu432 forms. 4. In contrast, Leu432 forms of CYP1B1 showed higher rates of oxidation of benzo[α]pyrene (to the 7,8-dihydoxy-7,8-dihydrodiol in the presence of epoxide hydrolase) than did the Val432 forms. 5. These results suggest that polymorphic human CYP1B1 variants may cause some altered catalytic specificity with 17β-oestradiol and benzo[α]pyrene and may influence susceptibilities of individuals towards endogenous and exogenous carcinogens.

[1]  T. Shimada,et al.  Roles of NADPH-P450 reductase in the O-deethylation of 7-ethoxycoumarin by recombinant human cytochrome P450 1B1 variants in Escherichia coli. , 2000, Protein expression and purification.

[2]  N. Roodi,et al.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. , 2000, Cancer research.

[3]  C. Wolf,et al.  Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. , 2000, Pharmacogenetics.

[4]  M. Ingelman-Sundberg,et al.  Characterization and functional analysis of two common human cytochrome P450 1B1 variants. , 2000, Archives of biochemistry and biophysics.

[5]  O. Gotoh,et al.  Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. , 2000, Pharmacogenetics.

[6]  Y. Fujii‐Kuriyama,et al.  Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  T. Shimada,et al.  Ethnic-related differences in the frequency distribution of genetic polymorphisms in the CYP1A1 and CYP1B1 genes in Japanese and Caucasian populations , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[8]  T. Shimada,et al.  Catalytic properties of polymorphic human cytochrome P450 1B1 variants. , 1999, Carcinogenesis.

[9]  T. Shimada,et al.  Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7, 8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. , 1999, Chemical research in toxicology.

[10]  J. Ward,et al.  Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  N. Roodi,et al.  Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. , 1998, Cancer research.

[12]  T. Shimada,et al.  Recombinant human cytochrome P450 1B1 expression in Escherichia coli. , 1998, Archives of biochemistry and biophysics.

[13]  H. Yamazaki,et al.  Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. , 1998, Chemical research in toxicology.

[14]  T. Shimada,et al.  Activation of procarcinogens by human cytochrome P450 enzymes. , 1998, Mutation research.

[15]  H. Yamazaki,et al.  Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. , 1998, Chemical research in toxicology.

[16]  A. Luch,et al.  Stable expression of human cytochrome P450 1B1 in V79 Chinese hamster cells and metabolically catalyzed DNA adduct formation of dibenzo[a,l]pyrene. , 1998, Chemical research in toxicology.

[17]  A. Child,et al.  Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. , 1998, American journal of human genetics.

[18]  J. Lupski,et al.  Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. , 1998, American journal of human genetics.

[19]  P. Strickland,et al.  Metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) by human cytochrome P4501B1. , 1997, Carcinogenesis.

[20]  F. Guengerich,et al.  Drug metabolism by Escherichia coli expressing human cytochromes P450 , 1997, Nature Biotechnology.

[21]  J. Sparano,et al.  Urinary estrogen metabolites and breast cancer: a case-control study. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[22]  H. Yamazaki,et al.  Aflatoxin B1 8,9-epoxide hydrolysis in the presence of rat and human epoxide hydrolase. , 1997, Chemical research in toxicology.

[23]  T. Sutter,et al.  Induction of cytochrome P450 1B1 and catechol estrogen metabolism in ACHN human renal adenocarcinoma cells , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  A. Dipple,et al.  Metabolic activation of benzo[g]chrysene in the human mammary carcinoma cell line MCF-7. , 1997, Cancer research.

[25]  H. Yamazaki,et al.  Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. , 1996, Cancer research.

[26]  J. Liehr,et al.  4-Hydroxylation of estrogens as marker of human mammary tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[28]  J. Liehr,et al.  4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[30]  F. Guengerich,et al.  Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. , 1993, Archives of biochemistry and biophysics.

[31]  E. Schuetz,et al.  17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. , 1992, Archives of biochemistry and biophysics.

[32]  T. Shimada,et al.  Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. , 1991, Chemical research in toxicology.

[33]  D. Nelson,et al.  Evolution of the cytochrome P450 genes. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.

[34]  F. Gonzalez,et al.  The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.

[35]  D. Nebert,et al.  Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. , 1982, Pharmacological reviews.

[36]  F. Guengerich,et al.  Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. , 1982, Biochemistry.

[37]  H. Gelboin.  Benzo[alpha]pyrene metabolism, activation and carcinogenesis: role and regulation of mixed-function oxidases and related enzymes. , 1980, Physiological reviews.

[38]  F. Guengerich,et al.  Rat and human liver microsomal epoxide hydratase. Purification and evidence for the existence of multiple forms. , 1979, The Journal of biological chemistry.

[39]  T. Iyanagi,et al.  Interaction between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane of phosphatidylcholine vesicles. , 1979, Biochimica et biophysica acta.

[40]  Y. Yasukochi,et al.  Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. , 1976, The Journal of biological chemistry.

[41]  S. Minakami,et al.  Incorporation of radioactive iron into cytochrome b5 and cytochrome P-450 of liver microsomes. , 1970, Journal of biochemistry.

[42]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[43]  H. Kamin,et al.  Microsomal triphosphopyridine nucleotide-cytochrome c reductase of liver. , 1962, The Journal of biological chemistry.

[44]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[45]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.

[46]  M. Noshiro,et al.  Immunochemical study on the electron pathway from NADH to cytochrome P-450 of liver microsomes. , 1978, Journal of biochemistry.